Secondary Stock OfferingsBy The Online Investor Staff, updated Thu., Feb. 27, 3:50 PM
|This Slide: #14 of 25|
Slide #14. Catalyst Biosciences, Inc. — Secondary Offering
Catalyst Biosciences, Inc. (NASDAQ:CBIO)
Date of Pricing:
Price Per Share:
Secondary Offering Details:
Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and other rare bleeding disorders, (the Company), today announced the pricing of an underwritten public offering of 4,615,385 shares of its common stock, offered at a price of $6.50 per share to the public. Additionally, the Company has granted the underwriters a 30-day option to purchase up to an additional 692,307 shares of its common stock. All of the shares in the offering are being offered by the Company. The offering is expected to close on or about February 18, 2020, subject to customary closing conditions.
Catalyst Biosciences is a clinical-stage biotechnology company focused on developing medicines to address hematology indications, including the treatment of hemophilia. Co. is focusing its product development efforts in the fields of hemostasis (the process that regulates bleeding). Co.'s principal product candidate is Factor VIIa (MarzAA), a Factor VIIa variant. MarzAA is being developed for the prophylactic treatment of individuals with hemophilia A and B with inhibitors. Co.'s second product candidate is Factor IX variants, a subcutaneously dosed Factor IX drug for the prophylactic treatment of individuals with hemophilia B.
Open the CBIO Page at The Online Investor »
Strong Buy (4.00 out of 4)
(ranked higher than approx. 96% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite